BAT Executive Dismisses Focus on Smoking Alternatives

Oct.12.2022
BAT Executive Dismisses Focus on Smoking Alternatives
BAT denies focus on smoking alternatives and plans to maximize growth from portfolio deployment. Transformation continues for a controversial industry.

The top executive of tobacco giant British American Tobacco (BAT) has rebuffed claims that the company will prioritize smoking alternatives, stating that such claims are too superficial.


Kingsley Wheaton, Chief Marketing Officer of British American Tobacco (BAT)


During an interview with City A.M., Chief Marketing Officer Kingsley Wheaton stated that although there may be "more advanced methods" for e-cigarette products in the northern hemisphere, this is driven solely by consumer demand and cigarette pricing.


Whittington stated that the deployment of BAT's investment portfolio, which includes Vuse and Glo, was aimed at achieving "maximum growth." He acknowledged that the tobacco industry remains "controversial" and that there is still a long way to go to achieve transformation. The company, which has a history of 120 years, has been undergoing a transformation plan to shift its customers from cigarette brands like Camel and Rothmans to its alternative products.


Wharton stated that, although growth of the company's new product line in markets such as South Africa, Kenya, and Pakistan has been slow, it is stable. The company is also attempting to identify suitable opportunities in developing markets.


Speaking to City A.M., Whitten said, "We need to provide scalable businesses and appropriate profits. Other regions in developing countries are taking advantage of this opportunity." He explained that some regions, such as Australia and Brazil, cannot achieve this due to strict regulations on tobacco alternatives.


He explained, "When cigarette prices rise, it becomes easier to distance oneself from the tobacco business." He cited the UK's success as an example, where 80% of the price of a pack of cigarettes is made up of taxes.


According to data from Action on Smoking and Health (ASH), the current number of smokers in the UK is five times that of 2012, accounting for approximately 8% of the total population.


Whittington stated that despite the fact that this FTSE 100-listed company's foray into e-cigarettes is still not profitable, it remains committed to its ambitious goal of new category tobacco comprising one-fifth of its overall revenue and profitability by 2025. For a company that serves 175 countries worldwide and generated over £25 billion in revenue in 2021, this goal may seem insignificant.


Statement:


This article is compiled from third-party sources and is intended for industry professionals for the purpose of exchanging and learning information.


This article does not represent the views of 2FIRSTS and 2FIRSTS is not able to confirm the authenticity or accuracy of the article's content. The translation of this article is solely for the purpose of industry communication and research.


Due to limitations in translation expertise, the compiled article may not express the same ideas as the original text. Please refer to the original text for accuracy.


2FIRSTS holds completely aligned positions with the Chinese government on any domestic, Hong Kong, Macau, Taiwan, and foreign-related expressions and stances.


The copyright of the compiled information belongs to the original media and authors. If there is any infringement, please contact us for removal.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
U.S. Customs Plan to Require Foreign Export Declarations Could Deal ‘Devastating’ Blow to China’s Vape Exports, Logistics gl Expert Says
A U.S. Customs and Border Protection proposal to collect foreign export declarations and other overseas customs documents could expose discrepancies in the value, classification and description of China-made vape shipments entering the United States. A veteran Chinese logistics professional told 2Firsts that the measure, if implemented, could undermine the all-inclusive shipping model used by some unauthorized vape exporters and push parts of the trade toward costlier underground channels. The risk extends beyond higher duties: accurately declared products may also be more readily identified as unauthorized e-cigarettes subject to FDA enforcement.
Special Report
Sep.07
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
On-Site Report | CTP Details PMTA Backlog, 180-Day Review Goal and sPMTA Process
FDA’s Center for Tobacco Products detailed new PMTA review data and process changes at the 2026 FDLI conference. Pending PMTAs fell from about 450,000 at the start of 2025 to 135,000 by September 2026. CTP also discussed its 180-day review goal, current sPMTA pilot, alternate-supplier planning, more than 50,300 pending SE reports, and lessons from the nicotine pouch pilot already being applied to ENDS review.
Regulations
Oct.07
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
2Firsts Hosts China Market Forum at InterTabac as Global Industry Attention to China’s Tobacco Sector Deepens
On September 16, 2Firsts hosted a China-focused industry forum during InterTabac in Dortmund, bringing together more than 30 participants from North America, Europe, India, South Korea and other markets. The session covered traditional tobacco, next-generation products, exports, technology, regulation and supply chains, while examining how China’s tobacco sector operates, where its transformation may be heading, and why its growing role matters increasingly to companies across the global tobacco and nicotine industry.
Sep.21